UBS Group AG boosted its position in shares of Synthetic Biologics Inc (NYSEMKT:SYN) by 10.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 214,357 shares of the company’s stock after buying an additional 20,038 shares during the period. UBS Group AG owned about 0.18% of Synthetic Biologics worth $135,000 at the end of the most recent reporting period.

Separately, Bank of New York Mellon Corp boosted its stake in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock worth $166,000 after buying an additional 7,962 shares in the last quarter.

Synthetic Biologics Inc (NYSEMKT SYN) traded down 0.926% during trading on Friday, reaching $0.535. 468,186 shares of the company’s stock traded hands. The firm has a 50 day moving average of $0.54 and a 200 day moving average of $0.63. Synthetic Biologics Inc has a 1-year low of $0.41 and a 1-year high of $1.90. The firm’s market capitalization is $65.21 million.

Synthetic Biologics (NYSEMKT:SYN) last released its earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.03. Equities analysts forecast that Synthetic Biologics Inc will post ($0.18) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Synthetic Biologics Inc (SYN) Position Raised by UBS Group AG” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at

Several brokerages recently issued reports on SYN. William Blair reaffirmed an “outperform” rating and set a $5.00 price objective on shares of Synthetic Biologics in a research note on Monday, May 22nd. Zacks Investment Research raised shares of Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research note on Wednesday. Finally, ValuEngine cut shares of Synthetic Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $4.51.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Institutional Ownership by Quarter for Synthetic Biologics (NYSEMKT:SYN)

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.